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Objective: The SF-SACRAH was developed to assess the involvement of the hand in 
rheumatoid arthritis (RA) and hand osteoarthritis (HOA) patients in daily clinical routines. 
In this pilot study, its sensitivity to change will be assessed longitudinally, and preliminary 
thresholds for patient relevant changes are derived.
Methods: Ninety-nine outpatients suffering from HOA (n = 55) or RA (n = 44) com-
pleted the SF-SACRAH once initially. After approximately 3 months, patients repeated 
the SF-SACRAH. At both visits, patients rated their satisfaction (PATSAT) with the state 
of their disease (1 =  very good to 5 = unsatisfactory). For assessing its sensitivity to 
change, SF-SACRAH changes in patients with stable, improving, or worsening con-
ditions according to PATSAT were calculated in HOA and RA patients. The respective 
medians and highest values were used to estimate patient relevant variation values. 
SF-SACRAH changes and positive or negative PATSAT changes in HOA as well as RA 
patients were analyzed by applying the Kruskal–Wallis test. In RA patients, the DAS28 
was also calculated. Spearman’s rho was calculated to correlate SF-SACRAH changes 
with the EULAR response criteria.
results: In HOA and RA patients, a statistically high correlation between PATSAT 
changes and SF-SACRAH values was revealed (p < 0.0001 in HOA and p < 0.01 in RA 
patients, respectively). The median changes in SF-SACRAH in patients with improving, 
stable, or worsening conditions according to PATSAT were HOA patients: PATSAT 
improving: ΔSF-SACRAH −1.6, PATSAT stable: ΔSF-SACRAH +0.8, PATSAT worsen-
ing: ΔSF-SACRAH +1.0; RA patients: PATSAT improving: ΔSF-SACRAH −0.9, PATSAT 
stable: ΔSF-SACRAH +0.2, PATSAT worsening: ΔSF-SACRAH +0.8. In RA patients, 
there is a moderate, but significant, correlation between DAS28 EULAR response criteria 
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and SF-SACRAH changes (ΔDAS28 improving >0.6: ΔSF-SACRAH −0.4, ΔDAS28 
<0.6: ΔSF-SACRAH +0.0, ΔDAS28 worsening >0.6: ΔSF-SACRAH +0.5; r = 0.433, 
p < 0.01).
conclusion: The SF-SACRAH constitutes a reliable tool for the assessment of hand 
impairment in patients with chronic rheumatic diseases. It proved to be sensitive to 
change in this short-term evaluation in both HOA and RA patients. Additionally, prelim-
inary patient variation values for improvement (−1.60) and deterioration (+1.0) could be 
derived.
Keywords: sF-sacrah, hand impairment, assessment methods, rheumatoid arthritis, hand osteoarthritis
inTrODUcTiOn
Hand osteoarthritis (HOA) and rheumatoid arthritis (RA) are 
the disorders seen in routine rheumatology practice that most 
frequently lead to impaired hand function. This symptom is 
arguably one of the most decisive determinants for a patient’s 
well-being and ability to work (1, 2). We developed a Score for the 
Assessment and Quantification of Chronic Rheumatic Affections 
of the Hands (SACRAH) (3), which, alongside the Australian/
Canadian osteoarthritis hand index (4), appeared to show the 
lowest diversity ratio and the highest percentage of linked internal 
classification of functioning, disability, and health in the available 
questionnaires for HOA (5). However, none of these question-
naires meet the requirements for use in daily clinical routines, as 
they are often comprised of too many questions, are too difficult 
or time consuming to calculate, or both. Moreover, it was shown 
that patients’ perspectives were related to the number of joints 
with a limited range of motion, but with no other symptoms. 
As such, patients’ opinions regarding joint function should be 
given a more prominent position in disease management (6). 
The M-SACRAH, developed from the SACRAH by reducing the 
number of questions, appeared to be sensitive to change after 
surgical intervention in rheumatoid hands (4, 7). Therefore, we 
pursued the objective of further developing a practical tool for the 
assessment of the involvement of the hand in rheumatic disorders. 
These efforts resulted in the Short Form Score for the Assessment 
and quantification of Chronic Rheumatic Affections of the Hands 
(SF-SACRAH), which is based on patients’ self-reports concern-
ing function, stiffness, and pain (8). The SF-SACRAH comprises 
five questions: three questions on function pertaining to “locking/
unlocking a door,” “fastening/unfastening a zip,” and “turning the 
pages of a newspaper”; one question on stiffness asking “how was 
your joint stiffness immediately after waking up in the morning”; 
and finally one question on pain asking about “pain in the hands 
at rest in the evening.” For the three questions concerning func-
tion, a score of 0 means “possible without any difficulty,” while a 
score of 10 means “impossible”; concerning stiffness a value of 0 
indicates “no stiffness” and 10 “unbearable stiffness” or similar; 
in the last question concerning pain, a score of 0 indicates “no 
pain” and 10 “unbearable pain.” The SF-SACRAH appeared to 
provide high internal consistency (standardized item alpha 0.731 
and 0.837, respectively) (8). Its Likert scales format from 0 to 10 
ensures easy completion and quick calculation in less than 1 min. 
This also makes it easy to use for non-rheumatologists.
It is the aim of this short-term pilot study to prove SF-SACRAH’s 
sensitivity to change under routine conditions, as it had already 
been shown for both other SACRAH questionnaires (3, 9). This is 
designed to enable longitudinal observations of functional hand 
impairment in daily routines and potential observations by elec-
tronic monitoring instruments (10, 11). Moreover, preliminary 
thresholds for patient relevant improvement and deterioration 
should be derived.
PaTienTs anD MeThODs
For this pilot study, HOA patients diagnosed according to the 
2009—EULAR recommendations using the patient’s history, 
clinical aspects, hand X-rays, and normal acute phase reac-
tions (12), as well as RA patients diagnosed according to the 
1987—ARA criteria for RA (13) were asked to complete the 
SF-SACRAH questionnaire at two consecutive appointments 
with the outpatient clinic. Patients were not included if they 
had any other disorder or were taking any medication that 
potentially influenced hand function, for example, fibromy-
algia, neurological disorders, peripheral vascular diseases, 
or the intake of aromatase inhibitors. Between the two visits, 
HOA patients were treated with a SYSADOA and analgesics or 
NSAIDs on demand, RA patients with conventional or biologi-
cal DMARDs, some with glucocorticoids and all with NSAIDs 
on demand.
To obtain another patient-related parameter, all patients were 
asked to rate their current satisfaction with the state of their 
disease (PATSAT) according to the Austrian school marking 
system (1 = excellent, 2 = good, 3 = average, 4 = adequate and 
5  =  unsatisfactory or, corresponding to the Anglo-American 
school system: 1  =  excellent, 2  =  good or above average, 
3 = average, 4 = below average or poor and 5 = unsatisfactory 
or fail). The Austrian school marking system resembles a Likert 
scale and is well established, which makes misinterpretations by 
the patients highly unlikely. Since no consistent tool has been 
proven to measure patients’ satisfaction with their state of disease 
in HOA or in RA patients, PATSAT was chosen to in order to 
derive a patient dependent parameter for the subjective disease 
status. A patient’s global assessment of the medical condition on a 
100-mm visual analog scale [VAS of Patient’s Global Assessment 
(VASPGA)] was not conducted as an alternative since it already 
forms part of the DAS28. Moreover, PATSAT was shown to have 
a significant correlation with composite disease activity indices, 
TaBle 1 | Patient’s characteristics.
ra (n = 44) hOa (n = 55)
Age median (min–max) 61.0 (32–72) 61.5 (46–73)
Gender (female %) 90.9 87.3
RF+ (%) 59.1
Disease duration months median (min–max) 59 (4–215) 24 (4–336)
Δ visit 1 and 2 months median (min–max) 3.5 (0.5–8.0) 3.0 (0.5–8.0)
Visit 1 Visit 2 Visit 1 Visit 2
DAS28 median (min–max) 3.96 (1.40–6.96) 3.93 (0.77–6.50) – –
PATSAT (1–5) median (min–max) 3 (1–5) 3 (1–5) 3 (1–5) 3 (1–5)
SF-SACRAH median (min–max) 2.4 (0.0–7.8) 2.6 (0.0–7.6) 2.2 (0.0–9.0) 2.0 (0.0–8.0)
SJC (out of 28) median (min–max) 2 (0–15) 2 (0–16) 0 (0–8) 0 (0–3)
TJC (out of 28) median (min–max) 4 (0–28) 3 (0–26) 1 (0–19) 1 (0–19)
VASPGA mm (0–100) median (min–max) 50 (0–98) 38 (0–100) 30 (0–78) 31 (0–74)
ESR first hour median (min–max) 18 (1–88) 21 (1–66) 11 (2–74) 12 (3–74)
DAS28, Disease Activity Score including 28 joints; ESR, erythrocyte sedimentation rate; HOA, hand osteoarthritis; max, maximum; min, minimum; mm, millimeter; PATSAT, patient’s 
satisfaction with the disease activity state; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count out of 28; SF-SACRAH, Short Form of the Score of Assessment 
of Chronic Rheumatic Affections of the Hand; TJC, Tender Joint Count out of 28; VAS, visual analog scale; VASPGA, VAS of patient’s global assessment.
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as well as with a patient’s attitude toward an increase or reduction 
in RA therapy (14).
We defined improvement in PATSAT as an observable positive 
change of least 1 point in PATSAT between visit 1 and visit 2, 
stability as no change in PATSAT, and deterioration as a negative 
change in PATSAT of at least 1 point between the two visits.
In RA patients, the Disease Activity Score, including a 28 
joint count and the erythrocyte sedimentation rate (ESR) 
first hour (DAS28ESR), was calculated (15) to obtain insights 
into disease activity and to correlate the functional status of 
the hands measured by SF-SACRAH and to obtain insights to 
the change of SF-SACRAH according to RA disease activity 
defined to be as stable or improving according to the EULAR 
response criteria (16). For the calculation of DAS28ESR, the 28 
predefined joints were assessed with regard to tenderness and 
swelling by experienced professionals. In addition, VASPGA 
and the ESR (first hour) were recorded to calculate DAS28ESR 
at both visits.
Changes in SF-SACRAH and PATSAT between visit 1 and visit 
2 were calculated for each HOA and RA individual patient and in 
addition, the DAS28 change for each RA patient. Subsequently, 
the relationship between SF-SACRAH changes and improve-
ment, stability or deterioration of PATSAT was determined in all 
groups by applying the Kruskal–Wallis test, as normal distribu-
tion could not be ascertained previously. Spearman’s rho was 
applied to correlate changes in SF-SACRAH with DAS28ESR 
EULAR response criteria in RA patients. Median changes in 
SF-SACRAH in relation to PATSAT improvement, stability, or 
deterioration were additionally calculated in order to estimate 
patient relevant SF-SACRAH changes. The highest median differ-
ence in SF-SACRAH for improvement or deterioration according 
to PATSAT will be used to define the preliminary patient relevant 
variation value. Since this study is considered a pilot study, no 
sample size calculation was performed.
As this study constitutes an analysis of existing, routinely 
compiled data and no direct personal patient data were pro-
cessed by the authors; Austrian law does not provide a basis for 
engagement of an ethics committee. Nevertheless, the study was 
informally brought to attention of the Lower Austrian Ethics 
Committee, which did not express any concerns related to this 
patient evaluation.
resUlTs
all Patients
Fifty-five patients suffering from HOA and 44 patients suffering 
from RA completed the SF-SACRAH questionnaire during two 
consecutive appointments at the outpatient clinic. For patient’s 
characteristics, see Table  1. The median time period between 
the two visits was 3.0 (min–max: 0.5–8) months in the HOA 
group and 3.5 (min–max: 0.5–8.0) months in the RA group. The 
SF-SACRAH for HOA patients at visit 1 was a median of 2.2 and 
then 2.0 during visit 2, whereas for RA patients, the median at 
visit 1 appeared to be 2.4 and then 2.6 during visit 2 (see Table 1).
sF-sacrah in hOa Patients
The SF-SACRAH improved in 57% of HOA patients, was stable in 
2%, and worse in 41% of patients (Figure 1A). In HOA patients, 
the median PATSAT amounted to 3.0 at visit 1 and also at visit 
2. In the PATSAT improvers, the median SF-SACRAH change 
was −1.6, in PATSAT-stable patients +0.8, while in the patients 
with worsening PATSAT, the respective SF-SACRAH change was 
+1.0 (Table 2; Figure 2A). When applying the Kruskal–Wallis 
test, changes in PATSAT and SF-SACRAH were found to be of 
statistically high significance (p < 0.0001).
sF-sacrah in ra Patients
The SF-SACRAH improved in 48%, was stable in 9%, and worse 
in 43% of RA patients (Figure 1B). As in the HOA patients, the 
RA patients demonstrated a median PATSAT of 3.0 at visit 1 and 
also at visit 2. The median SF-SACRAH change between the two 
visits was −0.9 in the patients showing improvement according 
to PATSAT, +0.2 in stable patients, and +0.8 in the worsening 
group (Table 3; Figure 2B). When applying the Kruskal–Wallis 
test, the RA patient group also revealed a statistically significant 
TaBle 2 | sF-sacrah changes according to PaTsaT changes in hOa 
patients.
hOa (n = 55) PaTsaT  
improving
PaTsaT  
stable
PaTsaT 
worsening
% patients 48 24 28
Δ SF-SACRAH 
median (min; max)
−1.6 (−4.8; +1.8) +0.8 (−3.4; +2.6) +1.0 (−0.4; +3.0)
HOA, hand osteoarthritis; n, number of patients; max, maximum; min, minimum; 
PATSAT, patient’s satisfaction with the disease activity state; SF-SACRAH, Short Form 
of the Score of Assessment of Chronic Rheumatic Affections of the Hand.
FigUre 2 | (a) SF-SACRAH changes in improving and worsening hand 
osteoarthritis (HOA) patients (reference PATSAT). (B) SF-SACRAH changes in 
improving and worsening rheumatoid arthritis (RA) patients (reference 
PATSAT).
B
A
FigUre 1 | (a) Changes in the SF-SACRAH between visit 1 and visit 2 in 
hand osteoarthritis (HOA) patients. (B) Changes in the SF-SACRAH between 
visit 1 and visit 2 in rheumatoid arthritis (RA) patients.
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relationship between the SF-SACRAH and PATSAT changes 
(p < 0.01).
At visit 1, the median DAS28 in the RA patients amounted to 
3.96, indicating moderate disease activity. There was no change 
in median disease activity at visit 2 (see Table 1).
Patients achieving at least a moderate EULAR response (DAS28 
positive change ≥0.6) showed a median SF-SACRAH reduction 
of −0.4 (min–max: −4.8; +0.8), stable patients demonstrated 
constant SF-SACRAH of ±0.0 (−1.8; +1.4), and when applying 
the reverse EULAR response criteria for RA worsening (patients 
with DAS28 negative changes ≥0.6), the respective SF-SACRAH 
change amounted to +0.5 (−3.4; +4.2). The correlation between 
the DAS28 changes and SF-SACRAH changes was found to be 
moderate but statistically significant, according to Spearman’s 
rank correlation coefficient (r = 0.433; p < 0.01).
Preliminary Patient relevant Variation 
Values for sF-sacrah
As shown in Tables 2 and 3, according to SF-SACRAH, we pro-
pose the following preliminary patient relevant variation values: 
for improvement a positive change of −1.6 and for deterioration 
a negative change of at least +1.0.
TaBle 3 | sF-sacrah changes according to PaTsaT changes in ra 
patients.
ra (n = 44) PaTsaT  
improving
PaTsaT  
stable
PaTsaT 
worsening
% patients 36 48 16
Δ SF-SACRAH  
median (min; max)
−0.9 (−4.8; +1.4) +0.2 (−1.8; +1.8) +0.8 (0.0; +2.2)
n, number of patients; max, maximum; min, minimum; PATSAT, patient’s satisfaction 
with the disease activity state; RA, rheumatoid arthritis; SF-SACRAH Short Form of the 
Score of Assessment of Chronic Rheumatic Affections of the Hand.
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DiscUssiOn
During this pilot study, the SF-SACRAH proved to be an appropri-
ate tool for assessing the severity of hand impairment due to HOA 
and RA and for according this impairment a numerical value. 
Additionally, the questionnaire’s sensitivity to change in relation 
to patient-related outcomes—in this case PATSAT—as well as 
composite indexes—in this study the DAS28ESR—could be 
demonstrated. These findings support the use of SF-SACRAH in 
clinical routine and investigative rheumatology to obtain greater 
understanding of affections of the hands in chronic rheumatic 
diseases such as HOA and RA. It is easily applicable as a patient-
related outcome measure and can be completed by the patient in 
less than 1 min. The value is extremely easy to calculate by adding 
five whole numbers and subsequently dividing the total by 5.
Regarding improvement, stability, and deterioration, the 
patient relevant changes revealed different results for HOA and 
RA patients. This finding may be due to the relatively small 
patient numbers, but could be also be disease related, which 
should inspire further research.
Interestingly, the values indicating patient relevant changes 
were numerically higher in HOA patients. Moreover, the numeri-
cal change in cases of deterioration is smaller than in cases of 
improvement. Another finding in RA patients seems worth 
mentioning: DAS28 changes which would meet the threshold 
for a moderate EULAR response (16) do not comply with the 
preliminary patient relevant SF-SACRAH changes. This finding 
corresponds to previous results, which showed a significant cor-
relation between DAS28 and SF-SACRAH in moderate and high 
disease activity, but an insignificant one in remission and low 
disease activity, a state which most of the patients included in this 
study had reached (17). Another RA study emphasized the lack 
of agreement between the patient’s and physician’s perception of 
RA activity changes. It also focused on the differences between 
improvement and deterioration in patient-related disease activity 
assessments (18).
The derived preliminary thresholds for patient relevant changes 
in hand impairment in RA and HOA certainly require further 
evaluation but may serve as a guideline for the future applica-
tion of the score in routine rheumatology and also for research 
purposes. Patient-related outcomes will become increasingly 
important as it is likely that in future, rheumatic disease manage-
ment will be facilitated by greater use of innovative electronic 
tools (19). To enable this, short and reliable questionnaires and 
thresholds for relevant disease activity changes form fundamental 
prerequisites. The SF-SACRAH proved to serve as an appropriate 
and simple tool (including for non-rheumatologists) to assess 
both the extent of the involvement of the hand and also hand 
impairment in HOA and RA. It will also serve as a useful tool to 
monitor the condition over time.
This study has several limitations. The first and most impor-
tant is the small number of patients included. Nonetheless, 
sensitivity to change could be demonstrated. The preliminary 
thresholds for improvement or deterioration in hand function 
according to SF-SACRAH should therefore be used with caution 
and further studies are mandatory. Second, PATSAT is not part of 
the Outcome Measures in Rheumatology (OMERACT) recom-
mended instruments for HOA or RA assessment. But as stated 
earlier, we searched for an additional patient-related assessment 
for HOA and RA patients. The OMERACT instrument VASPGA 
is used in the DAS28ESR as mentioned in the methods. PATSAT 
was shown to be significantly correlated with composite disease 
activity indices as well as to a patient’s attitude toward increase 
or reduction of therapy (14). Research into patient-related out-
comes such as the SF-SACRAH requires innovative approaches. 
Relating a functional score to a clinical score for disease activity 
may not be the most appropriate way to demonstrate sensitivity 
to change or to search for improvement or deterioration, as they 
should constitute different parts of one assessment. Third, this is 
a short-term investigation, and therefore, we cannot reach any 
conclusions on whether our results are consistent in the long 
term or even for an electronic survey. Fourth, SF-SACRAH and 
its mother instruments are not examined in different hand dis-
ability stages. However, we are convinced that each patient with 
compromised function of his or her hands has to reach a better 
functional stage through our treatment. The SF-SACRAH could 
be an appropriate tool to monitor these efforts, but more research 
is mandatory.
Neither the application of any questionnaire nor any index can 
substitute for careful clinical patient examination (20). However, 
since rheumatologists focus increasingly on individualized treat-
ment regimens, questionnaires may provide useful ways to iden-
tify patients requiring particular attention. No single measure can 
serve as a “gold standard” in the treatment of individual patients 
in most rheumatic diseases (21). The SF-SACRAH constitutes 
one easy option for routine monitoring, enabling health-care 
professionals to obtain reliable information about the disease 
course and focusing on hand impairment.
cOnclUsiOn
• SF-SACRAH proved its reliability and sensitivity to change.
• Preliminary patient relevant thresholds could be derived for 
RA and HOA patients, namely, −1.6 for improvement and 
+1.0 for deterioration.
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